In this episode, we dive deep into the growing influence of private equity on Institutional Review Boards (IRBs), the challenges of maintaining transparency and avoiding conflicts of interest, and the explosion of data collection in modern clinical trials. We also discuss the promises and pitfalls of AI in research, share personal stories from the field, and reflect on the latest industry news and conferences.